NGS Streamlines Biomarker Testing in Solid Tumors
Chen, PharmD, MS, BCOP, CPP, discusses how next-generation sequencing improves biomarker testing and treatment planning in solid tumors.
- Experts including Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, share insights on the topic.
- Others such as Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Daniel Lefler, MD, also contribute to the discussion.
- Additional experts like Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Roboz, MD, provide their perspectives.
No direct quotes are available in the provided text.
Author's summary: NGS improves biomarker testing in solid tumors.
More News
- Billie Eilish Calls on Billionaires to Do More for People in Need
- ‘Join hands’: Xi urges stable supply chains after sealing Trump truce
- Meta's big AI gamble just cost Mark Zuckerberg two spots on the billionaire's index
- AFLW Team Selection: One change made as winger notches historic milestone
- V Levels must build on the best of BTECs, not erase them